Literature DB >> 12515073

Arteriovenous sheathotomy for branch retinal vein occlusion.

Mark T Cahill1, Sharon Fekrat.   

Abstract

Branch vein occlusion is a significant cause of visual loss attributed to retinal vascular disease and is second only to diabetic retinopathy. BVO nearly always occurs at an AV crossing because of compression of the vein by the artery, resulting in hemodynamic abnormalities in the vein, including thrombus formation, reversal of flow toward the artery, and AV collateral formation. Relatively little information is available on the natural history of BVO; most of what exists is derived from clinical trials, including the BVOS. Current treatment options focus on treating sequelae of the occluded venous branch, such as macular edema, retinal neovascularization, vitreous hemorrhage, and traction retinal detachment. A novel therapeutic approach is decompression of the AV crossing, which has had promising initial results including restoration of vision and reversal of hemodynamic abnormalities. A prospective, controlled, clinical trial is being organized to determine the role of AV sheathotomy in the treatment of BVO.

Entities:  

Mesh:

Year:  2002        PMID: 12515073     DOI: 10.1016/s0896-1549(02)00040-8

Source DB:  PubMed          Journal:  Ophthalmol Clin North Am        ISSN: 0896-1549


  8 in total

1.  Visual acuity and multifocal electroretinographic changes after arteriovenous crossing sheathotomy for macular edema associated with branch retinal vein occlusion.

Authors:  Eun Jee Chung; William R Freeman; Hyoung Jun Koh
Journal:  Retina       Date:  2008-02       Impact factor: 4.256

2.  Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion.

Authors:  Eun Jee Chung; Hyo Lee; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-19       Impact factor: 3.117

3.  Branch retinal vein occlusion and vitreovascular traction: a preliminary spectral domain OCT case-control study.

Authors:  Francisco J Ascaso; Esteban Padgett; Esther Núñez; Laura Villén; Andrzej Grzybowski; José A Cristóbal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03       Impact factor: 3.117

4.  Annexin A3 is necessary for parallel artery-vein alignment in the mouse retina.

Authors:  Katie Huang; Angela M Crist; Nehal R Patel; Avery Blanks; Kelsey Carter; Ondine Cleaver; Stryder M Meadows
Journal:  Dev Dyn       Date:  2020-02-14       Impact factor: 3.780

5.  Angiographic findings in arteriovenous dissection (sheathotomy) for decompression of branch retinal vein occlusion.

Authors:  Thomas Kube; Nicolas Feltgen; Mona Pache; Julia Herrmann; Lutz Lothar Hansen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-03       Impact factor: 3.117

6.  The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins.

Authors:  Alessandro Fantin; Quenten Schwarz; Kathryn Davidson; Eduardo M Normando; Laura Denti; Christiana Ruhrberg
Journal:  Development       Date:  2011-08-18       Impact factor: 6.868

Review 7.  NRP1 function and targeting in neurovascular development and eye disease.

Authors:  Claudio Raimondi; James T Brash; Alessandro Fantin; Christiana Ruhrberg
Journal:  Prog Retin Eye Res       Date:  2016-02-27       Impact factor: 21.198

Review 8.  Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability.

Authors:  Alice Plein; Alessandro Fantin; Christiana Ruhrberg
Journal:  Microcirculation       Date:  2014-05       Impact factor: 2.628

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.